Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847024 | 1.00 | MAPT (0.47) | MAPTLMNAGAAMEN1ALDH1A1 | |
| SCHEMBL1406081 | 1.00 | MAPT (0.47) | MAPTLMNAGAAMEN1ALDH1A1 | |
| Water SCHEMBL5174358 | 0.99 | MAPT (0.46) | MAPTLMNAGAAMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5099552 | 0.99 | MAPT (0.48) | MAPTLMNAGAAMEN1ALDH1A1 | |
| Water SCHEMBL7801345 | 0.99 | MAPT (0.46) | MAPTLMNAGAAMEN1ALDH1A1 | |
| Water SCHEMBL5174360 | 0.99 | MAPT (0.46) | MAPTLMNAGAAMEN1ALDH1A1 | |
| Water SCHEMBL5176169 | 0.99 | MAPT (0.46) | MAPTLMNAGAAMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27712434 | 0.99 | MAPT (0.48) | MAPTLMNAGAAMEN1ALDH1A1 | |
| Water SCHEMBL5176172 | 0.99 | MAPT (0.46) | MAPTLMNAGAAMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7810063 | 0.99 | MAPT (0.48) | MAPTLMNAGAAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081906-A1 | CEFDINIR INTERMEDIATE | KREMMINGER PETER | 2008-04-03 | — | — | US | claimed |
| US-20060025586-A1 | Cefdinir intermediate | SANDOZ AG (CH) | 2006-02-02 | — | — | US | claimed |
| EP-1554289-A1 | A CEFDINIR INTERMEDIATE | Sandoz AG (CH) | 2005-07-20 | — | — | EP | claimed |
| WO-2004016623-A1 | A CEFDINIR INTERMEDIATE | SANDOZ AG (CH) | 2004-02-26 | — | — | WO | claimed |
| JP-8041041-A | — | — | None | — | — | JP | disclosed |
| JP-8041041-A | — | — | None | — | — | JP | disclosed |
| EP-1554289-B1 | A CEFDINIR INTERMEDIATE | SANDOZ AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-7825241-B2 | Cefdinir intermediate | SANDOZ AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20080081906-A1 | CEFDINIR INTERMEDIATE | KREMMINGER PETER | 2008-04-03 | — | — | US | disclosed |
| EP-1842852-A1 | A CEFDINIR INTERMEDIATE | Sandoz AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| US-7250508-B2 | Cefdinir intermediate | SANDOZ AG (CH) | 2007-07-31 | — | — | US | disclosed |
| EP-1786793-A1 | TERTIARY AMINE SALTS OF 2-(2-AMINOTHIAZOLE-4-YL)-2-(ACYLOXYIMINO)ACETIC ACID | Sandoz AG (CH) | 2007-05-23 | — | — | EP | disclosed |
| EP-1340751-A1 | PROCESS FOR PRODUCING ANHYDRIDE OF AMINOTHIAZOLE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
| JP-H0841041-A | METHOD FOR PRODUCING 2-(2-AMINOTHIAZOL-4-YL)-2-ACETOXYIMINOACETIC ACID OR ITS DERIVATIVE | TOKUYAMA CORP | 1996-02-13 | — | — | JP | disclosed |
| JP-H0841041-A | METHOD FOR PRODUCING 2-(2-AMINOTHIAZOL-4-YL)-2-ACETOXYIMINOACETIC ACID OR ITS DERIVATIVE | TOKUYAMA CORP | 1996-02-13 | — | — | JP | disclosed |
| EP-0185221-B1 | PROCESS FOR THE PREPARATION OF AMINOTHIAZOLYLACETIC-ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1990-09-26 | — | — | EP | disclosed |
| US-4888429-A | Process for producing allyl aminothiazole acetate intermediates | HOFFMANN-LA ROCHE INC. (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0214462-A2 | 3,7-Disubstituted-3-cephem compounds and processes for production of the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-18 | — | — | EP | disclosed |
| EP-0185220-A2 | Intermediates for the preparation of cephalosporins | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-06-25 | — | — | EP | disclosed |
| EP-0185221-A2 | Process for the preparation of aminothiazolylacetic-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1986-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025586-A1 | Cefdinir intermediate | PCMT1, SULT1E1, AASDHPPT | MAPT 2935/4885LMNA 4843/4885GAA 4356/4885 |
| US-20080081906-A1 | CEFDINIR INTERMEDIATE | PCMT1, AASDHPPT, SULT1E1 | MAPT 2866/4885LMNA 4844/4885GAA 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.